ELISA for VEGF

Details ELISA for VEGF ELISA for VEGF

2005-02-15

2005-02-15

Chin, Christopher L. (Department: 1641)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S007210, C435S007500, C435S007940, C435S070210, C435S452000, C435S330000, C435S335000, C435S337000, C435S344000, C435S975000, C436S518000, C436S528000, C436S531000, C436S548000, C436S172000, C436S809000, C436S813000, C530S388230, C530S388250, C530S388800, C530S389200, C530S389300, C530S389700, C530S391100

Reexamination Certificate

active

06855508

ABSTRACT:
The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA method and kits for VEGF as an antigen were developed to detect VEGF levels in biological samples from animal models and human patients and are used as a diagnostic/prognostic index.

REFERENCES:
patent: 3645852 (1972-02-01), Axen et al.
patent: 3691016 (1972-09-01), Patel
patent: 3720760 (1973-03-01), Bennich et al.
patent: 3969287 (1976-07-01), Jaworek et al.
patent: 4195128 (1980-03-01), Hildebrand et al.
patent: 4229537 (1980-10-01), Hodgins et al.
patent: 4247642 (1981-01-01), Hirohara et al.
patent: 4330440 (1982-05-01), Ayers et al.
patent: 4376110 (1983-03-01), David et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5434087 (1995-07-01), Beggs et al.
patent: 5620845 (1997-04-01), Gould et al.
patent: 5985579 (1999-11-01), Buechler et al.
patent: 8245424 (1996-09-01), None
patent: 11178593 (1999-07-01), None
Aiello et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,”New England J. of Medicine,vol. 331, No. 22, pp. 1480-1487 (1994).
Anthony et al., “Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins,”Ann. Clin. Biochem.,vol. 34, pp. 276-280 (1997).
Baccala et al., “Serum vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer,”Urology,vol. 51, No. 2, pp. 327-332 (1998).
Baker et al., “Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia,”Obstet. Gynecol,vol. 86, pp. 815-821 (1995).
Banks et al.; “Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1,”Molecular Human Reproduction,vol. 4, No. 4, pp. 377-386 (1998).
Berkman et al.; “Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms,”J. Clin. Invest.,vol. 91, No. 1, pp. 153-159 (1993).
Brekken et al., “Selective Inhibition of Vascular Endothelial Growth Factor (VEGF) Receptor 2 (KDR/Flk-1) Activity by a Monoclonal Anti-VEGF Antibody Blocks Tumor Growth in Mice,”Cancer Research,vol. 60, pp. 5117-5124 (2000).
Brekken et al., “Vascular Endothelial Growth Factor as a Marker of Tumor Endothelium,”Cancer Research,vol. 58, pp. 1952-1959 (1998).
Brown et al., “Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract,”Cancer Research,vol. 53, No. 19, pp. 4727-4735 (1993).
Brown et al., “Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer,”Human Pathology,vol. 26, No. 1, pp. 86-91 (1995).
de Vries et al., “The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor,”Sciencevol. 255, pp. 989-991 (1992).
Dvorak et al., “Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis,”American Journal of Pathology,vol. 146, No. 5, pp. 1029-1039 (1995).
Ferrara et al., “The biology of vascular endothelial growth factor,”Endocrine Reviews,vol. 18, No. 1, pp. 4-25 (1997).
Ferrari et al., “Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients,”European Journal of Cancer,vol. 32A, No. 13, pp. 2368-2369 (1996).
Folkman et al., “Angiogenesis,”Journal of Biological Chemistry,vol. 267, pp. 10931-10934 (1992).
Fujisaki et al., “Circulating vascular endothelial growth factor in patients with colorectal cancer,”American Journal of Gastroenterology,vol. 93, No. 2, pp. 249-252 (1998).
Furhmann-Benzakein et al, “Elevated Levels of Angiogenic Cytokines in the Plasma of Cancer Patients,”Int. J. Cancer,vol. 85, pp. 40-45 (2000).
Gasparini et al., “Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma,”Journal of National Cancer Institute,vol. 89, No. 2, pp. 139-147 (1997).
Hanatani et al., “Sensitive chemiluminescence enzyme immunoassay for vascular endothelial growth factor/vascular permeability factor in human serum,”Biosci. Biotechnol. Biochem.,vol. 59, No. 10, pp. 1958-1959 (1995).
Horak et al., “Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer,”Lancet,vol. 340, No. 8828, pp. 11204-1124 (1992).
Hornig et al., “Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA,”J. Immunol. Methods,vol. 226, pp. 169-177 (1999).
Houck et al., “Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms,”Journal of Biological Chemistry,vol. 267, pp. 26031-26037 (1992).
Houck et al. “The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA,”Mol. Endocrinol.,vol. 5, pp. 1806-1814 (1991).
Keck et al., “Disulfide Structure of the Heparin Binding Domain in Vascular Endothelial Growth Factor: Characterization of Posttranslational Modifications in VEGF,”Archives of Biochemistry&Biophysics,vol. 344, No. 1, pp. 103-113 (1997).
Keyt et al., “Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors: Generation of receptor-selective VEGF variants by site-directed mutagenesis,”Journal of Biological Chemistryvol. 271, No. 10, pp. 5638-5646 (1996).
Keyt et al., “The Carboxyl-terminal Domain (111-165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency,”Journal of Biological Chemistry,vol. 271, No. 13, pp. 7788-7795 (Mar. 29, 1996).
Kim et al., “The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies,”Growth Factors,vol. 7, No. 1, pp. 53-64 (1992).
Klagsbrun et al., “Regulators of angiogenesis,”Ann. Rev. Physiol.,vol. 53, pp. 217-239 (1991).
Kohn, E., “Angiogenesis in ovarian carcinoma: a formidable biomarker,”Cancer,vol. 80, No. 12, pp. 2219-2221 (1997).
Kondo et al., “Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients,”Biochimica et Biophysica Acta,vol. 1221, No. 2, pp. 211-214 (1994).
Leith et al., “Secretion rates and levels of vascular endothelial growth factor in clone A or HCT-8 human colon tumor cells as a function of oxygen concentration,”Cell Proliferation,vol. 28, No. 8, pp. 415-430 (1995).
Leung et al., “Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen,”Science,vol. 246, pp. 1306-1309 (1989).
Lin et al., “Preclinical Pharmacokinetics, Interspecies Scaling, and Tissue Distribution of a Humanized Monoclonal Antibody against Vascular Endothelial Growth Factor,”J. Pharm. Exp. Ther.,vol. 288, No. 1, pp. 371-378 (1999).
Lopez et al., “Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes,”Invest. Ophthalmol. Vis. Sci.,vol. 37, No. 5, pp. 855-868 (1996).
Macchiarini et al., “Relation of neovascularisation to metastasis of non-small-cell lung cancer,”Lancet,vol. 340, No. 8812, pp. 145-146 (1992).
Mattern et al., “Association of vascular end

Affiliated with

Also associated with

Rating

ELISA for VEGF does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with ELISA for VEGF, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ELISA for VEGF will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3502312